Ligand, Trevena, Schering-Plough deal

Ligand will screen its combinatorial library against 24 targets provided by Trevena to identify compounds targeting GPCRs. Trevena will have exclusive, worldwide rights to sublicense any resulting compounds and is responsible for all development and commercialization. Ligand is eligible for milestones on each target over the two-year deal. Trevena's drug discovery portfolio is focused on cardiovascular and CNS indications. ...